$UFPT (-5,42%)

UFP Technologies CFO Ronald Lataille acquires $91,635 worth of common stock.

In a recent transaction filed with the Securities and Exchange Commission, Ronald J. Lataille, Chief Financial Officer of UFP Technologies Inc. acquired 400 shares of the company's common stock.

I will probably add a few more next week to improve my purchase price a little.

Figures were great, for a short time there was also a breakout of ~ +10% which did not last long 💁🏼‍♂️

See $UFPT (-5,42%) as a strong, profitable company and executive remuneration has also been increased, so I think the share price will recover noticeably in the near future.

Sooo entry found. Didn't think the figures and outlook were that bad

why is the share stuck? there were also very good figures yesterday $UFPT (-5,42%)

does anyone have an idea

$UFPT (-5,42%)

UFP Technologies, Inc. ( UFPT ) announced on Tuesday a 41.1 percent year-over-year increase in fourth quarter earnings.

Net income for the quarter totaled $16.38 million, an increase from $11.61 million a year ago. Earnings per share amounted to USD 2.10, an increase compared to USD 1.51 in the previous year. Adjusted earnings amounted to 19.16 million US dollars or 2.46 US dollars per share, an increase compared to 12.64 million US dollars or 1.64 US dollars per share in the previous year.

Net sales increased by 41.9 percent from USD 101.49 million in the previous year to USD 144.07 million.

so I think it's going up now,

last tranche

is stabilizing $UFPT (-5,42%) at the moment? Soil?

🫡🙏🏼

so finally got a foot in the door right at support

if it falls further i will buy 1 more time

$UFPT (-5,42%) UFP Tech 🚀🌕

reported third quarter EPS of $2.39, $0.53 more than the analyst estimate of $1.86.

Revenue for the quarter amounted to $145.17M, compared to the average estimate of $132.03M.

Unfortunately, I didn't buy enough in advance :(

but that's the way it is 🙈

$UFPT (-5,42%) I've had it on my watchlist for some time.

I entered cautiously, am still waiting for the upcoming figures to then possibly buy some more 🥳

Outperformer in weak stock market times.

Hello my dears,

Due to the current weakness on the stock markets, I took a deep dive into the engine room. I have found a long-term outperformer. As the chart comparison with the S&P 500 shows.

Due to the high P/E valuation, the stock is still on my watch list to buy in due course.

When would be a good time for you to buy?

But now let's take a look at the company

UFP Technology $UFPT (-5,42%)

company. And as usual, there is a short and sweet analysis with important key figures that can be increased.

(in USD)

Turnover: 2024: 479.30 million 2025: 567.99 million

Net income: 2024: 44.92 million

2025: 57.74 million

2026: 66.22 million

Free cash flow: 2024: 32.70 million 2025: 50.50

EbiT margin: 2024: 15.97% 2025: 16.79%

Earnings per share: 2024: 7.01 2025: 8.26

KGV: 2024: 45.8. 2025: 38.9

Profit growth: 2024: 20.75%

2025: 17,19%,

About UFP Technologies, Inc.

UFP Technologies is a designer and manufacturer of comprehensive solutions for medical devices, sterile packaging and other advanced customized products. UFP is a key link in the medical device supply chain and a valued outsourcing partner for most of the world's leading medical device manufacturers. The company's disposable and single patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods and orthopedic implants.

The company has acquired AQF Medical, a specialist in medical device solutions, for around 48 million US dollars. This is UFP's fourth acquisition in a series of strategic moves that also includes the purchase of ARJ Enterprises, Welch Fluorocarbon and Marble Medical.

Among other things, UFP is a supplier of

$ISRG (-5,49%)

The company's expansion strategy was positively received by analysts. Lake Street Capital Markets has maintained a Buy rating on UFP Technologies and raised the price target to USD 392. The company forecasts a strong Q2 earnings report and GAAP earnings per share of $9 in 2026, which could potentially exceed $10 in 2027. However, KeyBanc has reiterated its Sector Weight rating on UFP Technologies on valuation grounds.

These recent developments reflect UFP Technologies' commitment to its growth strategy and financial targets, which include a revenue growth rate of 12-18%, a gross profit margin of 28-31% and an operating profit margin of 15-18%. The company's recent acquisitions are expected to positively impact its financial performance and expand its medical device product offering.